• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    2/9/24 3:17:09 PM ET
    $NEO
    Precision Instruments
    Health Care
    Get the next $NEO alert in real time by email
    SC 13G/A 1 neoa1_20924.htm BROWN ADVISORY INC neoa1_20924.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    NeoGenomics, Inc.
    (Name of Issuer)
    (Title of Class of Securities)
    64049M209
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 64049M209
           
    1
    NAME OF REPORTING PERSON
    Brown Advisory Incorporated ("BAI")
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    52-2112409
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Brown Advisory Incorporated is a Maryland Corporation.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    8,248,003
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    9,536,307
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,536,307
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    12
    TYPE OF REPORTING PERSON
    HC (Control Entity)
    CUSIP No.: 64049M209
           
    1
    NAME OF REPORTING PERSON
    Brown Investment Advisory & Trust Company ("BIATC")
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    52-1811121
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Brown Investment Advisory & Trust Company is a Maryland Trust Company.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    47,173
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    47,173
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    47,173
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0.1%
    12
    TYPE OF REPORTING PERSON
    BK (Bank)
    CUSIP No.: 64049M209
           
    1
    NAME OF REPORTING PERSON
    Brown Advisory LLC (BALLC)
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    26-0680642
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Brown Advisory LLC is a Maryland Limited Liability Corporation.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    8,200,830
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    9,489,134
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,489,134
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.4%
    12
    TYPE OF REPORTING PERSON
    IA (Investment Adviser)
    CUSIP No.: 64049M209
    ITEM 1(a). NAME OF ISSUER:
    NeoGenomics, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    ITEM 2(a). NAME OF PERSON FILING:
    Brown Advisory Incorporated ("BAI")
    Brown Investment Advisory & Trust Company ("BIATC")

    Brown Advisory LLC (BALLC)
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    901 South Bond Street, Suite #400
    Baltimore, Maryland 21231
    ITEM 2(c). CITIZENSHIP:
    Brown Advisory Incorporated is a Maryland Corporation.
    Brown Investment Advisory & Trust Company is a Maryland Trust Company.
    Brown Advisory LLC is a Maryland Limited Liability Corporation.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    ITEM 2(e). CUSIP NUMBER:
    64049M209
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [X]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    Brown Advisory Incorporated ("BAI") is a parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    Brown Investment Advisory & Trust Company ("BIATC") is a bank as defined in Section 3(a)(6) of the Act (15U.S.C.78c)
    Brown Advisory LLC ("BALLC") is an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E)
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    6,337,008
    (b) Percent of class:
    5%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Brown Advisory Incorporated ("BAI") - 8,248,003
    Brown Investment Advisory & Trust Company ("BIATC")
    - 47,173
    Brown Advisory LLC (BALLC) - 8,200,830
    (ii) shared power to vote or to direct the vote:
    Brown Advisory Incorporated ("BAI") - 0
    Brown Investment Advisory & Trust Company ("BIATC")
    - 0
    Brown Advisory LLC (BALLC) - 0
    (iii) sole power to dispose or direct the disposition of:
    Brown Advisory Incorporated ("BAI") - 0
    Brown Investment Advisory & Trust Company ("BIATC")
    - 0
    Brown Advisory LLC (BALLC) - 0
    (iv) shared power to dispose or to direct the disposition of:
    Brown Advisory Incorporated ("BAI") - 9,536,307
    Brown Investment Advisory & Trust Company ("BIATC")
    - 47,173
    Brown Advisory LLC (BALLC) - 9,489,134
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The total securities being reported are beneficially owned by investment companies and other managed accounts of direct/indirect subsidiaries of BAI (listed above). These subsidiaries may be deemed to be beneficial owners of the reported securities because applicable investment advisory contracts provide voting and/or investment power over securities.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Brown Advisory Incorporated (BAI) is a parent holding company filing this schedule on behalf of the following
    subsidiaries pursuant to Rule 13d-1(b)(1)(ii)(G) under the Securities Exchange Act of 1934:
    Brown Investment Advisory & Trust Company (BIATC) BK (Bank)
    Brown Advisory LLC (BALLC) IA (Investment Adviser)
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 64049M209
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 09 2024
    Brown Advisory Incorporated ("BAI")
    By:
    /s/
    Name:
    Brett D. Rogers
    Title:
    General Counsel
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $NEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEO

    DatePrice TargetRatingAnalyst
    7/30/2025Buy → Neutral
    BTIG Research
    7/29/2025Outperform → Mkt Perform
    William Blair
    5/15/2025Neutral
    Guggenheim
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    More analyst ratings

    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    12/30/25 7:07:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 10-Q filed by NeoGenomics Inc.

    10-Q - NEOGENOMICS INC (0001077183) (Filer)

    10/28/25 4:05:09 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    10/28/25 7:09:29 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    Guggenheim initiated coverage on NeoGenomics

    Guggenheim initiated coverage of NeoGenomics with a rating of Neutral

    5/15/25 8:12:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

    NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court's August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics' favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics' motion for summary judgment and held that Natera's asserted patent claims are invalid for claiming ineligible subject

    12/15/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Present New ctDNA Research at SABCS 2025

    Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR® 1.0 assay for the detection of molecular residual disease (MRD) will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. NeoGenomics will present new data from the SURVIVE HERoes Phase III trial and the CLEVER study, both of which used RaDaR 1.0 circulating tumor DNA (ctDNA) testin

    12/10/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott covered exercise/tax liability with 11,938 shares, decreasing direct ownership by 6% to 176,394 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    12/9/25 4:16:26 PM ET
    $NEO
    Precision Instruments
    Health Care

    Pres & Chief Operating Officer Stone Warren covered exercise/tax liability with 8,776 shares, decreasing direct ownership by 8% to 99,504 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    12/3/25 5:17:13 PM ET
    $NEO
    Precision Instruments
    Health Care

    EVP, GC & Business Development Olivo Alicia C exercised 8,977 shares at a strike of $10.05 and sold $250,992 worth of shares (20,916 units at $12.00), decreasing direct ownership by 28% to 31,083 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    11/28/25 4:18:22 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

    6/24/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    3/18/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics Reports Third Quarter 2025 Results

    Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025. Third Quarter 2025 Highlights As Compared To Third Quarter 2024   Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18%

    10/28/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domesti

    10/7/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care